Investor Sofinnova Partners SAS
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Sofinnova Partners SAS . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-04-30 13G/A QNCX / Quince Therapeutics, Inc. 2,397,711 1,197,711
2025-02-14 13G QNCX / Quince Therapeutics, Inc. 2,155,694 2,397,711
2024-08-06 13G/A QNCX / Quince Therapeutics, Inc. 2,178,150 2,155,694
2024-02-12 13G QNCX / Quince Therapeutics, Inc. 2,178,150
2019-02-14 13G/A PRQR / ProQR Therapeutics N.V. 3,625,925 2,764,194
2018-02-14 13G/A PRQR / ProQR Therapeutics N.V. 2,769,125 3,625,925
2016-02-16 13G/A FLXN / Horizon Funds - Horizon Flexible Income ETF 1,901,491
2016-02-16 13G/A PRQR / ProQR Therapeutics N.V. 2,769,125
2016-02-16 13G/A DBVT / DBV Technologies S.A. - Depositary Receipt (Common Stock) 997,002
2015-02-17 13G PRQR / ProQR Therapeutics N.V. 2,874,324
2015-02-17 13G DBVT / DBV Technologies S.A. - Depositary Receipt (Common Stock) 2,549,834
2015-02-11 13G FLXN / Horizon Funds - Horizon Flexible Income ETF 2,061,684
2013-12-12 13G/A CLVS / Clovis Oncology Inc 928,669
2013-11-27 13G CLVS / Clovis Oncology Inc 2,102,371